Optimization of neuroprotective therapy for ischemic stroke in the acute period

Abstract

The article demonstrates the world experience of neoroprotective therapy in the treatment of ischemic stroke in the acute perod. The feasibility of prescribing metabolic drugs is not completely clear, the effectiveness has not been definitively proven, despite numerous studies that show only trends. The drug does not reliably improve the neurological status of patients after a stroke, but it reduces the ten-year risk of stroke. Thus, the mechanisms of action of drugs and data from experimental and clinical studies, including those after neoroprotective therapy and with the inclusion of drugs for primary and secondary prevention of ischemic stroke, have been analyzed.